← Back to headlines
Moderna Reports Q3 Revenue Projections and Norovirus Trial Miss
Moderna expects 55% of its second-half revenue in Q3 and reiterates its 2026 growth target, despite a norovirus trial missing an early metric.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
